Latest Breaking News On - Ahmanson translational theranostics division - Page 4 : comparemela.com

MELBOURNE, Australia, June 27, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118). New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting, and for staging and informing treatment decisions. TLX250-CDx PET/CT detected more lesions in liver and bone than diagnostic CT imaging alone. This reinforces the performance of this investigational diagnostic imaging agent across all analyses, with previously presented data showing an excellent overall sensitivity and specificity of 86% and 87%, respectively, together with high intra-reader agreement.[1], [2] The results were featured in an oral presentation delivered on Monday, 26 June 2023 (C

Los angelesUnited statesUnited kingdomKyahn williamsonSociety of nuclear medicinePharmacology at university of californiaAustralian securities exchangeAustralian therapeutic goods administrationPrnewswire telix pharmaceuticals limitedDrug administrationHealth canadaCorporate communicationsEuropean unionTelix pharmaceuticalsPharmaceuticals limitedJeremie calais